Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with […]
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
A fat dividend yield can signal a screaming buy or a slow-motion disaster, and the difference hides in coverage math most investors never check. Six well-known names are flashing the exact warning signs that tend to show up just before a payout gets cut.
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
Key Stats for Pfizer StockCurrent Price: $27. 93Target Price (Mid): ~$29Street Target: ~$29Potential Total Return: ~5%Annualized IRR: ~1.
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.
AT&T, Verizon, and Pfizer all trade under $50 a share, but a low entry price and genuine value are two very different things, and only one of these three high-yield names carries a coverage story that should make income investors nervous.
Rising global concern around AI safety at the Trump Xi summit puts a spotlight on where artificial intelligence is already deeply embedded in real-world decisions. Few areas are as critical as healthcare. That is where algorithms do not just optimise ads, they help doctors interpret scans, triage patients, and support drug discovery. This article highlights three stocks from our transformative AI healthcare screener that capture that shift. The three stocks below are a small sample of what is...
These are among the highest-yielding stocks on the S&P 500.
Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure. The 23.9% 1 year return has reset expectations for Pfizer, which puts more weight on whether its earnings base can carry that higher price level. Fresh...
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief international commercial officer and executive vice president. Speaking with Chris Schott at a company event
Eli Lilly just posted a quarter that crushed estimates on every major metric, yet the stock has spent the past month getting punished anyway. One of Wall Street's biggest banks thinks the selloff created the most compelling entry point in the GLP-1 giant's recent history.
These companies are committed to rewarding shareholders.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
A $219M construction loan for 100 Wall Street highlights the accelerating office-to-residential conversion wave in New York.
Earlier this month, Pfizer’s CEO Albert Bourla told investors at Morgan Stanley’s Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing mix of newer therapies. At the same time, Pfizer’s agreement to share a portion of any additional overseas pricing revenue with the U.S. Department of Health and Human Services, alongside management’s...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
